GlassScriptPhysician profile
Anne Vaz
NPI 1104145762
$1,971.85
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $452 · 2023: $284 · 2024: $332 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $282.08 | 2021-2025 | |
| Pfizer INC. | $267.00 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.11 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $109.78 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $92.37 | 2021-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $85.10 | 2021 | |
| Abbott Laboratories | $84.50 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $76.69 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $66.82 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $64.22 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $57.69 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $56.72 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $54.92 | 2021-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $39.43 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.68 | 2021-2022 | |
| Renalytix Ai, INC. | $16.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.72 | 2022 | |
| Neos Therapeutics, LP | $14.25 | 2023 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $13.46 | 2023 | Arexvy, Shingrix |
| Sanofi Pasteur INC. | $13.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.49 | 2022 | |
| Currax Pharmaceuticals LLC | $11.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.65 | 2021 | |
| Genentech USA, INC. | $4.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Vaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.